SG11202007316TA - Use of circulating microparticles to stratify risk of spontaneous preterm birth - Google Patents
Use of circulating microparticles to stratify risk of spontaneous preterm birthInfo
- Publication number
- SG11202007316TA SG11202007316TA SG11202007316TA SG11202007316TA SG11202007316TA SG 11202007316T A SG11202007316T A SG 11202007316TA SG 11202007316T A SG11202007316T A SG 11202007316TA SG 11202007316T A SG11202007316T A SG 11202007316TA SG 11202007316T A SG11202007316T A SG 11202007316TA
- Authority
- SG
- Singapore
- Prior art keywords
- preterm birth
- spontaneous preterm
- circulating microparticles
- stratify risk
- stratify
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91045—Acyltransferases (2.3)
- G01N2333/91051—Acyltransferases other than aminoacyltransferases (general) (2.3.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/976—Trypsin; Chymotrypsin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Primary Health Care (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Databases & Information Systems (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Software Systems (AREA)
- Evolutionary Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862624713P | 2018-01-31 | 2018-01-31 | |
US201962796557P | 2019-01-24 | 2019-01-24 | |
PCT/US2019/016192 WO2019152745A1 (en) | 2018-01-31 | 2019-01-31 | Use of circulating microparticles to stratify risk of spontaneous preterm birth |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202007316TA true SG11202007316TA (en) | 2020-08-28 |
Family
ID=67479487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202007316TA SG11202007316TA (en) | 2018-01-31 | 2019-01-31 | Use of circulating microparticles to stratify risk of spontaneous preterm birth |
Country Status (7)
Country | Link |
---|---|
US (1) | US20210057039A1 (en) |
EP (1) | EP3746048A4 (en) |
JP (1) | JP2021512318A (en) |
KR (1) | KR20200140797A (en) |
CN (1) | CN111989090A (en) |
SG (1) | SG11202007316TA (en) |
WO (1) | WO2019152745A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10928402B2 (en) | 2012-12-28 | 2021-02-23 | Nx Prenatal Inc. | Treatment of spontaneous preterm birth |
EP2956768B1 (en) * | 2013-02-13 | 2023-10-18 | Promega Corporation | Method for assessing performance of an instrument with liquid chromatography and mass spectrometry functionalities |
JP2019505815A (en) | 2015-12-04 | 2019-02-28 | エヌエックス・プリネイタル・インコーポレイテッドNX Prenatal Inc. | Use of circulating microparticles to stratify natural preterm birth risk |
US11854706B2 (en) * | 2019-10-20 | 2023-12-26 | Cognitivecare Inc. | Maternal and infant health insights and cognitive intelligence (MIHIC) system and score to predict the risk of maternal, fetal and infant morbidity and mortality |
CA3189254A1 (en) * | 2020-08-17 | 2022-02-24 | Brice L. GAUDILLIERE | Compositions and methods of predicting time to onset of labor |
CN113791224B (en) * | 2021-09-18 | 2023-12-01 | 浙江大学 | Early warning method for recurrent abortion caused by unknown reasons based on follicular fluid protein expression |
CN114047277B (en) * | 2022-01-10 | 2022-04-05 | 天津云检医学检验所有限公司 | Urine metabolite feature and early birth prediction kit for predicting premature birth |
KR20230145829A (en) * | 2022-04-11 | 2023-10-18 | 의료법인 성광의료재단 | Mass Spectrum Analysis Method for Prediction of High-Risk Pregnancies using machine learning |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10928402B2 (en) * | 2012-12-28 | 2021-02-23 | Nx Prenatal Inc. | Treatment of spontaneous preterm birth |
US20140186332A1 (en) * | 2012-12-28 | 2014-07-03 | NX Pharmagen | Biomarkers of preterm birth |
ES2836127T3 (en) * | 2013-03-15 | 2021-06-24 | Sera Prognostics Inc | Biomarkers and methods to predict preterm birth |
PL3311158T3 (en) * | 2015-06-19 | 2023-11-27 | Sera Prognostics, Inc. | Biomarker pairs for predicting preterm birth |
JP2019505815A (en) * | 2015-12-04 | 2019-02-28 | エヌエックス・プリネイタル・インコーポレイテッドNX Prenatal Inc. | Use of circulating microparticles to stratify natural preterm birth risk |
-
2019
- 2019-01-31 SG SG11202007316TA patent/SG11202007316TA/en unknown
- 2019-01-31 CN CN201980023243.8A patent/CN111989090A/en active Pending
- 2019-01-31 KR KR1020207024733A patent/KR20200140797A/en not_active Application Discontinuation
- 2019-01-31 WO PCT/US2019/016192 patent/WO2019152745A1/en unknown
- 2019-01-31 EP EP19748288.8A patent/EP3746048A4/en active Pending
- 2019-01-31 JP JP2020541768A patent/JP2021512318A/en active Pending
-
2020
- 2020-07-31 US US16/945,644 patent/US20210057039A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210057039A1 (en) | 2021-02-25 |
CN111989090A (en) | 2020-11-24 |
JP2021512318A (en) | 2021-05-13 |
WO2019152745A1 (en) | 2019-08-08 |
KR20200140797A (en) | 2020-12-16 |
EP3746048A1 (en) | 2020-12-09 |
EP3746048A4 (en) | 2021-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202007316TA (en) | Use of circulating microparticles to stratify risk of spontaneous preterm birth | |
EP3384076A4 (en) | Use of circulating microparticles to stratify risk of spontaneous preterm birth | |
HK1252859A1 (en) | Humanized and affinity matured antibodies to fcrh5 and methods of use | |
HK1243967A1 (en) | Methods of providing skin care using phototherapy | |
HK1258914A1 (en) | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases | |
IL253118A0 (en) | Methods of treating inflammatory diseases | |
IL252587A0 (en) | Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer | |
HK1253373A1 (en) | Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases | |
HUE054828T2 (en) | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same | |
HK1252037A1 (en) | Methods of treating inflammatory diseases | |
IL269096A (en) | Treatment of glycogen storage disease iii | |
HUE057484T2 (en) | Lncrnas for therapy and diagnosis of cardiac hypertrophy | |
PL3277272T3 (en) | Methods of stratifying patients for treatment with retinoic acid receptor-agonists | |
PT3250600T (en) | Treatment of autoimmune disorders with cd154 antibodies | |
GB201401465D0 (en) | Use of cladribine for treating autoimmune inflammatory disease | |
EA201791901A1 (en) | ANTAGONISTS OF NEUROKININ-3 RECEPTOR FOR THE THERAPEUTIC OR COSMETOLOGICAL TREATMENT OF EXTREME FATS ON THE BODY | |
ZA201901090B (en) | Therapeutic combinations to treat red blood cell disorders | |
HK1258463A1 (en) | Non-invasive determination of risk for sudden cardiac death | |
RS59341B2 (en) | Treatment of anodized aluminum and alloys | |
IL273489A (en) | Use of nor-ursodeoxycholic acid for reducing liver fat | |
IL267231A (en) | Methods of treating diseases associated with ilc2 cells | |
PT3064185T (en) | Stretcher support to be installed in health compartments of ambulances | |
HUP1500192A2 (en) | Use of mannooligosaccharides for treating human inflammatory bowel diseases | |
GB201514909D0 (en) | Treatment of autoimmune diseases | |
GB201418096D0 (en) | Novel polymorph for use in treatment of inflammatory skin and pruritic disorders |